Current approaches to diagnosing and treating eosinophilic granulomatosis with polyangiitis: The 2015 international guidelines


The 2015 international guidelines for the diagnosis and treatment of eosinophilic granulomatosis with polyangiitis, formerly known as the Churg-Strauss syndrome, are detailed and an attempt is made to expand an evidence base, by attracting more recent available publications. The new guidelines should not be regarded as final standards; these are primarily to extend the possibilities of choosing a personified management strategy for patients with eosinophilic granulomatosis with polyangiitis and to serve as the starting point for further in-depth investigations.


  1. Jennette JC, Falk RJ, Bacon PA еt аl. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11.
  2. Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, Baslund B, Brenchley P, Bruchfeld A, Chaudhry AN, Cohen Tervaert JW, Deloukas P, Feighery C, Gross WL, Guillevin L, Gunnarsson I, Harper L, Hrušková Z, Little MA, Martorana D, Neumann T, Ohlsson S, Padmanabhan S, Pusey CD, Salama AD, Sanders JS, Savage CO, Segelmark M, Stegeman CA, Tesař V, Vaglio A, Wieczorek S, Wilde B, Zwerina J, Rees AJ, Clayton DG, Smith KG. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367(3):214-223.
  3. Mahr A, Guillevin L, Poissonnet M еt аl. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg—Strauss syndrome in a French urban multiethnic population in 2000: a capture—recapture estimate. Arthritis Rheum. 2004;5:92-99.
  4. Guerry MJ, Brogan P, Bruce IN, D’Cruz DP, Harper L, Luqmani R, Pusey CD, Salama AD, Scott DG, Savage CO, Watts RA, Jayne DR. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012;51(4):634-643
  5. Cordier J-F, Humbert M, Guillevin L, Jayne D, Jennette JC, Lazor R, Mahr A, Wechsler ME. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Int Med. 2015;26 (7):545-553.
  6. Robson J, Doll H., Suppiah R, Flossmann O, Harper L, Höglund P, Jayne D, Mahr A, Westman K, Luqmani R. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford). 2015;54(3):471-481.
  7. Muñoz SA, Gandino IJ, Orden AO, Allievi A. Rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. Reumatol Clin. 2015;11(3):165-159. doi: 10.1016/j.reuma.2014.08.005.
  8. Fanouriakis A, Kougkas N, Vassilopoulos D, Fragouli E, Repa A, Sidiropoulos P. Rituximab for eosinophilic granulomatosis with polyangiitis with severe vasculitic neuropathy: Case report and review of current clinical evidence. Semin Arthritis Rheum. 2015;45(1):60-66. PMID: 25908179. doi: 10.1016/j.semarthrit.2015.03.004.
  9. Бекетова Т.В., Насонов Е.Л., Александрова Е.Н. и др. Российский опыт применения моноклональных антител к В-лимфоцитам (Ритуксимаб) при системных васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами (предварительные результаты российского регистра НОРМА). Научно-практическая ревматология. 2014;52(2):147-159. doi: 10.14412/1995-4484-2014-147-158.
  10. Koike H, Akiyama K, Saito T, Sobue G; Research Group for IVIg for EGPA/CSS in Japan. Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a multicenter, double-blind trial. J Neurol. 2015;262(3):752-759.
  11. Choi HK, Liu S, Merkel PA, Colditz GA, Niles JL. Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies. J Rheumatol. 2001;28(7):1584-1590.
  12. Comarmond C, Pagnoux C, Khellaf M, Cordier JF, Hamidou M, Viallard JF еt аl. Eosinophilic granulomatosis with polyangiitis (Churg—Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013;65(1):270-281.
  13. Keogh KA, Specks U. Churg—Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med. 2003;115:284-290.
  14. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP еt аl. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33:1094-1100.
  15. TaylorMR, Keane CT, O’Connor P,Mulvihill E, Holland C. The expanded spectrum of toxocaral disease. Lancet. 1988;1(8587):692-695.
  16. Siddiqui AA, Berk SL. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis. 2001;33(7):1040-1047.
  17. Lanham J, Elkon K, Pusey C, Hughes G. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg—Strauss syndrome. Medicine. 1984;63:65-81.
  18. Guillevin L, Lhote F, Gayraud M еt аl. Prognostic factors in polyarteritis nodosa and Churg—Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996;75:17-28.
  19. Стрижаков Л.А., Моисеев С.В., Коган Е.А., Паша С.П., Чурганова Л.Ю., Диттерле В.Е., Новиков П.И, Семенкова Е.Н., Мухин Н.А. Поражение сердца при системных васкулитах: патогенетические звенья, значение факторов риска развития сердечно-сосудистых осложнений и диагностика. Терапевтический архив. 2014;12(2):35-42.
  20. Grayson PC, Monach PA, Pagnoux C, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, Koening CL, Langford CA, Maksimowicz-McKinnon K, Seo P, Specks U, Ytterberg SR, Merkel PA; Vasculitis Clinical Research Consortium. Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. Rheumatology (Oxford). 2015;54(8):1351-1359.
  21. Herrmann K, GrossWL, Moosig F. Extended follow-up after stopping mepolizumab in relapsing/refractory Churg—Strauss syndrome. Clin Exp Rheumatol. 2012;30(1, Suppl. 70):S62-65.
  22. Dallos T, Heiland GR, Strehl J, Karonitsch T, GrossWL,Moosig F еt аl. CCL17/thymus and activation-related chemokine in Churg—Strauss syndrome. Arthritis Rheum. 2010;62(11):3496-3503.
  23. Vaglio A, Strehl JD, Manger B, Maritati F, Alberici F, Beyer C еt аl. IgG4 immune response in Churg—Strauss syndrome. Ann Rheum Dis. 2012;71(3):390-393.
  24. Zwerina J, Bach C,Martorana D, JatzwaukM, Hegasy G,Moosig F еt аl. Eotaxin-3 in Churg—Strauss syndrome: a clinical and immunogenetic study. Rheumatology (Oxford). 2011;50(10):1823-1827.
  25. Polzer K, Karonitsch T, Neumann T, Eger G, Haberler C, Soleiman A еt аl. Eotaxin-3 is involved in Churg—Strauss syndrome — a serum marker closely correlating with disease activity. Rheumatology (Oxford). 2008;47(6):804-808.
  26. Moosig F, Bremer JP, Hellmich B, Holle JU, Holl-Ulrich K, Laudien M еt аl. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg—Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis. 2013;72(6):1011-1017.
  27. Guillevin L, Pagnoux C, Seror R et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine. 2011;90:19-27.
  28. de Groot K, Harper L, Jayne D еt аl. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150:670-680.
  29. Harper L, Morgan M, Walsh M еt аl. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis. 2012;71:955-960.
  30. Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P еt аl. Rituximabversus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771-1780.
  31. Jones R, Cohen Tervaert J, Hauser T еt аl. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211-220. doi: 10.1056/NEJMoa0909169.
  32. Stone J, Merkel P, Spiera R еt аl.; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232. doi: 10.1056/NEJMoa0909905.
  33. Bouldouyre M-A, Cohen P, Guillevin L. Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome. Ann Rheum Dis. 2009;68(4):606. doi: 10.1136/ard.2008.093773.
  34. Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroidsparing treatment option in patients with Churg—Strauss syndrome. J Allergy Clin Immunol. 2010;125(6): 1336-1343.
  35. Moosig F, GrossWL, Herrmann K, Bremer JP, Hellmich B. Targeting interleukin-5 in refractory and relapsing Churg—Strauss syndrome. Ann Intern Med. 2011;155(5):341-343.
  36. Herrmann K, Gross WL, Moosig F. Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome. Clin Exp Rheumatol. 2012;30(1 Suppl 70):S62-65.
  37. Tsurikisawa N, Taniguchi M, Saito H, Himeno H, Ishibashi A, Suzuki S, Akiyama K. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol. 2004;92(1):80-87.
  38. Rutberg SA, Ward DE, Roth BJ. Churg-Strauss syndrome and pregnancy: successful treatment with intravenous immunoglobulin. J Clin Rheumatol. 2002;8(3):151-156.
  39. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C; European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36-44.



Abstract - 84

PDF (Russian) - 27


Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2020 Beketova T.V., Volkov M.Y., Nasonov E.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies